Senores Pharmaceuticals Limited has informed the Exchange regarding acquisition of 6730 equity shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals, subsidiary of the Company.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals is buying 6,730 equity shares of its US-based subsidiary Havix Group Inc. (D/B/A Aavis Pharmaceuticals) from a public-category shareholder at USD 181 per share, totalling about USD 1.22 million in cash. After the deal, Senores' combined stake in Havix (with its wholly owned unit Senores Pharmaceuticals Inc.) will rise from 70.07% to 73.04%. The deal was approved by the Management Committee on July 10, 2025 and is expected to close within 30 days, subject to FEMA approvals. Havix manufactures and supplies finished pharmaceutical formulations in the US, with FY25 turnover of USD 19.87 million, up from USD 8.81 million in FY23, showing strong growth. The transaction is at arm's length and is not a related-party deal.
This is a minor stake consolidation in an already-controlled subsidiary, so the financial impact is small. However, it strengthens Senores' control over a fast-growing US pharma business, which posted 56% revenue growth in FY25, potentially adding modestly to consolidated earnings going forward.